Next Article in Journal
Kinetics of Pectin Biopolymer Facial Erosion Characterized by Fluorescent Tracer Microfluidics
Next Article in Special Issue
Synthesis and Characterization of Polyethylene Glycol-Grafted Photoreactive Polyethylene Glycols for Antibiofouling Applications
Previous Article in Journal
Electroactive Oxidized Alginate/Gelatin/MXene (Ti3C2Tx) Composite Hydrogel with Improved Biocompatibility and Self-Healing Property
Previous Article in Special Issue
Morphological Dependence of Breast Cancer Cell Responses to Doxorubicin on Micropatterned Surfaces
 
 
Article
Peer-Review Record

Bioabsorbable Carboxymethyl Starch–Calcium Ionic Assembly Powder as a Hemostatic Agent

Polymers 2022, 14(18), 3909; https://doi.org/10.3390/polym14183909
by Young-Gwang Ko 1, Byeong Nam Kim 2, Eun Jin Kim 2, Ho Yun Chung 3, Seong Yong Park 4, Young-Jin Kim 5 and Oh Hyeong Kwon 1,*
Reviewer 1: Anonymous
Polymers 2022, 14(18), 3909; https://doi.org/10.3390/polym14183909
Submission received: 18 August 2022 / Revised: 13 September 2022 / Accepted: 14 September 2022 / Published: 19 September 2022
(This article belongs to the Special Issue Polymer Surface and Interfacial Control for Biomedical Applications)

Round 1

Reviewer 1 Report

In this manuscript, the authors prepared an ionic assembly of carboxymethyl starch and calcium, which showed elevated hemostatic performance, rheology, adhesion force, C3a complement activation and quick in vivo biodegradation. The paper was well organized and I have the following questions.

1.     Fig. 7. The number of samples used in the C3a complement system activation assay should be disclosed and the error bars should be shown.

2.     Fig. 9. (1) Why did the authors compare the in vivo biodegradation of OOZFIX and Arista AH? (2) Did authors evaluate the biosafety (e.g., tissue toxicity) of hemostatic powder on rats?

Author Response

Please, see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

The scientific paper "Bioabsorbable carboxymethyl starch–calcium ionic assembly powder as a hemostatic agent” aimed to investigate the hemostatic performance of a bioabsorbable powder with decreased desorption. I can make the following considerations:

1)      in 2.8 add ethical approval protocol number and approval date

2)      Section 3 (Results) should be modified for results and discussion. Or the discussion should be done in another section. There is a low number of references (only 18). Therefore, authors need to compare their findings with previous literature, increasing the scientific basis of their research with more references.

3)      Insert study limitations

4)      Remove numerical data from the conclusion.

Author Response

Please, see the attachment.

Author Response File: Author Response.pdf

Round 2

Reviewer 2 Report

No comments

Back to TopTop